Earl Howe Appointed As ICR President
News Oct 20, 2008
In his new role Earl Howe will not only be a figurehead for the ICR but he will also act as an ambassador for the clinical research industry helping to provide introductions to key advocates. His position within Parliament will also offer ICR opportunities to hold top level briefings and events with parliamentary contacts helping to influence industry policies.
Earl Howe has been the opposition spokesperson for health and social services in the House of Lords for more than 10 years, he has extensive knowledge of the medical and clinical research industry and is a member of the pharmaceuticals and mental health all-party groups.
On his new role, Earl Howe, said: “I am delighted to be appointed president of the ICR. I have long had a professional interest in clinical research and I am personally relishing the opportunity of helping to further raise the profile of this important area of medicine.
“I have already met with the ICR’s chair Susan Ollier, chief executive Dr John Hooper and the rest of the board and I am inspired by their enthusiasm and drive for improvements in the industry.”
Susan Ollier, chair of the ICR, is looking forward to working with Earl Howe. She commented: “Earl Howe is the first president of the ICR and his appointment in the organisation’s 30th year of operation reflects the mature position and stature that the Institute has reached in its development.
“To support the appointment of Earl Howe, we will be appointing a vice-president, based in mainland Europe, to help support our expanding membership base in Europe and continue to widen the learning and development opportunities for our members.”
The ICR is the largest professional clinical research body in Europe and India. Its vision is to be internationally recognised as the premier organisation for clinical research and respected as a key influencer, promoting knowledge and understanding throughout the industry.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018